Protein A Potentiates Lymphokine-Activated Killer Cell Induction in Normal and Melanoma Patient Lymphocytes

References

• Catalona W. J., Ratliff T. L., McCool R. E. Interferon induced by S. aureus protein A augments natural killing and ADCC. Nature 1981; 291: 77
   PubMed Web of Science ®Google Scholar
• Cowan F. M., Klein D. L., Armstrong C. R., Pearson J. W. Augmentation and inhibition of delayed hypersensitivity by Staphylococcus aureus protein A. Biomedicine 1979; 30: 241
   PubMedGoogle Scholar
• Kronvall G., Gewurz J. Activation and inhibition of IgG-mediated complement fixation by Staphylococcal protein A. Clin. Exp. Immunol. 1970; 7: 211
   PubMed Web of Science ®Google Scholar
• Prasad A. K., Singh K. P., Saxena A. K., Mathur N., Ray P. K. Increased macrophage activity in protein A treated tumor regressor animals. Immunopharmacol. Immunotoxicol. 1987; 9: 541
   PubMed Web of Science ®Google Scholar
• Singh K. P., Saxena A. K., Prasad A. K., Dwivedi P. D., Zaidi S. I. A., Ray P. K. Effect of protein A on mast cell numbers and macrophage phagocytic activity. Immunopharmacol. Immunotoxicol. 1987; 9: 281
   PubMed Web of Science ®Google Scholar
• Ray P. K. Suppressor control as a modality of cancer treatment : perspectives and prospects in the immunotherapy of malignant disease. Plasma Therapy 1982; 3: 101
   Google Scholar
• Steele G., Jr, Ankerest J., Sjogren J. O. Alteration in in vitro anti-tumor activity of tumor-bearer sera by absorption with Staphylococcus aureus Cowan I. Int. J. Cancer 1974; 14: 83
   Web of Science ®Google Scholar
• Ray P. K., Bandyopadhyay. Inhibition of rat mammary tumor growth by purified protein A : a potential antitumor agent. Immunol. Commun 1983; 12: 1
   PubMedGoogle Scholar
• Ray P. K., Bandyopadhyay S., Dohadwala M., Canchanapan P., Mobini J. Antitumor activity with nontoxic doses of protein A. Cancer Immunol. Immunother. 1984a; 18: 29
   PubMed Web of Science ®Google Scholar
• Ray P. K., McLaughlin D., Allen P., Bandyopadhyay S., Idiculla A., Bassett J. G., Cooper D. R. Adsorption of plasma from tumor bearing host over protein A containing nonviable Staphylococcus aureus Cowan I, possible mechanism of antitumor reaction. J. Biol. Res. Modif. 1984b; 3: 293
   PubMedGoogle Scholar
• Ray P. K., McLaughlin D., Mohammed J., Idiculla A., Rhoads J. E., Jr, Mark R., Bassett J. G., Cooper D. R. Ex vivo immunoadsorption of IgG or its complex a new modality of cancer treatment. Immune Complexes and plasma exchanges in cancer patients, B. Erroui, C. Rosenfeld. North-Holland, Elsevier 1981; 197
   Google Scholar
• Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer-cel phenomenon, Lysis of natural-killer resistant fresh solid tumor cells by interleukin-2-activated lymphocytes. J. Exp. Med. 1982; 155: 1823
   PubMed Web of Science ®Google Scholar
• Ortaldo J. R., Mason A., Overton R. Lymphokine-activated cells. Analysis of progenitors and effectors. J. Exp. Med. 1986; 164: 1193
   PubMed Web of Science ®Google Scholar
• Robb R. J., Munch A., Smith K. A. T-cell growth factor receptors : quantitation, specificity and biological relevance. J. Exp. Med. 1981; 154: 1455
   PubMed Web of Science ®Google Scholar
• Robb R. J., Greene W. C., Rusk C. M. Low and high affinity cellular receptors for interleukin-2: implications for the level of Tac antigen. J. Exp. Med. 1984; 160: 1126
   PubMed Web of Science ®Google Scholar
• Uchiyama T., Broder S., Waldman T. A. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac(+) cells. J. Immunol. 1981; 126: 1393
   PubMed Web of Science ®Google Scholar
• Tsudo M., Kozak R., Goldman C. K., Waldmann T. A. Demonstration of a non-Tac peptide, that binds interleukin 2 : a potential participant in a multichain interleukin 2 receptor complex. Proc. Nat. Acad. Sci. (Wash) 1986; 83: 9694
   PubMed Web of Science ®Google Scholar
• Sharon M., Klausner R. D., Cullen B. R., Chizzonite R., Leonard W. J. Novel interleukin 2 receptor subunit detected by cross-linking under high-affinity conditions. Science 1986; 234: 859
   PubMed Web of Science ®Google Scholar
• Siegel J. P., Sharon M., Smith P. L., Leonard W. J. The IL-2 receptor β chain (P70): role in mediating signals for LAK, NK and proliferative activities. Science 1987; 38(2)75
   Google Scholar
• Taniguchi T., Matsui H., Fusita T. Structure and expression of a clonal cDNA for human interleukin-2. Nature (Lond.) 1983; 302: 305
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Immunotherapy of cancer using interleukin-2 : Current status and future prospects. Immunol. Today 1988; 9(Part, 2)58
   PubMedGoogle Scholar
• Eberlein T. J., Rosenstein M., Rosenberg S. A. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J. Exp. Med. 1982; 156: 385
   PubMed Web of Science ®Google Scholar
• Rosenstein M., Eberlein T. J., Rosenberg S. A. Adoptive immunotherapy of established syngeneic tumor: role of T lymphoid subpopulations. J. Immunol. 1987; 132: 2117
   Google Scholar
• Mule J. J., Shu S., Schwartz S. L., Rosenberg S. A. Successful adoptive immunotherapy of established pulmonary metastasis with LAK cells and recombinant IL-2. Science 1984; 255: 1487
   Google Scholar
• Mazumder A., Rosenberg S. A. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J. Exp. Med. 1984; 159: 495
   PubMed Web of Science ®Google Scholar
• Lafreniere R., Rosenberg S. A. Successful immunotherapy of experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 1985; 45: 3735
   PubMed Web of Science ®Google Scholar
• Anderson T. M., Ibayashi Y., Tokuda Y., Coloquhoun S. D., Holmes E. C., Golub S. H. Effects of systemic recombinant interleukin 2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. Cancer Res. 1988; 48: 1180
   PubMed Web of Science ®Google Scholar
• Shau Ibayashi H. Y., Tokuda Y., Sarna G. P., Altrock B., Golub S. H. Regulation of NK cytotoxicity in vivo in patients receiving IL-2. The Role of Interleukin-2 Activated Killer Cells in Cancer, E. Lotzova, R. B. Herberman. CRC Press, Boca Raton, FL 1989, In Press
   Google Scholar
• Pross H. F., Baines M. G., Rubin P., Shragge P., Patterson M. S. Spontaneous human lymphocyte mediated cytotoxicity against tumor target cells. The quantitation of natural killer cell activity. J. Clin. Immunol. 1981; 1: 51
   PubMed Web of Science ®Google Scholar
• O'Malley J. A., Nassbaum-Blumenson A., Sheedy D., Grossmayer B. J., Ozer H. Identification of the T cell subset that produces human gamma interferon. J. Immunol. 1982; 128: 2522
   PubMed Web of Science ®Google Scholar
• Olenescu A., Hristecu S., Sjoquist J., Ghetie V. Correlation between the triggering of proliferation and the potentiation of NK activity induced by protein A in human lymphocytes. Immun. Lett. 1983; 6: 231
   PubMed Web of Science ®Google Scholar
• Dosset J., Kronvall G., Williams R. C., Jr, Quite P. G. Antiphagocytic effects of Staphylococcal protein A. J. Immunol. 1969; 103: 1405
   Web of Science ®Google Scholar
• Patel P. C., Stefanescu-Soare I., Menezes J. Staphylococcal protein A enhances natural killing activity against lymphoid tumor cell lines. Int. J. Cancer 1981; 28: 277
   Web of Science ®Google Scholar
• Ratliff T. R., McDermott R. P., Poepping N. J., Oakley D. M., Shapiro A., Catalona W. Production of gamma interferon by human T and null cells and its regulation by macrophages. Cell Immunol. 1982; 74: 111
   PubMed Web of Science ®Google Scholar
• Ducatenzeiler A., Menezes J. Human gama interferon induction by Staphylococcal protein A: effector cells, kinetics and the effect of prostaglandin, indomethacin, ibrufen and aspirin. Int. J. Immunopharmac. 1988; 10: 81
   PubMed Web of Science ®Google Scholar
• Fleischer B. Induction of T-cell growth factor synthesis in human peripheral blood lymphocytes by Staphylococcal protein A. J. Immun. Meth. 1981; 47: 191
   PubMed Web of Science ®Google Scholar
• Hansson M., Beran M., Andersson B., Kiessling R. Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells. J. Immunol. 1989; 129: 126
   Google Scholar
• Chouaib S., Bertoglio J., Blay J. Y., Marchiol F. C., Fradelizi D. Lymphokine-activated killer generation pathway : Synergy between tumor necrosis factor and interleukin-2. Proc. Nat. Acad. Sci. (Wash) 1988; 85: 6875
   PubMed Web of Science ®Google Scholar
• Blay J. Y., Bertoglio J., Fradelizi D., Chouaib S. Functional alterations of IL-2 and TNF in the differentiation of LGL into LAK effectors. Int. J. Cancer 1989; 44: 498
   Web of Science ®Google Scholar
• Lee J. C., Truneh A., Smith M. F., Jr, Tsang K. Y. Induction of interleukin 2 receptor (Tac) by tumor necrosis factor in YT cells. J. Immunol. 1987; 139: 1935
   PubMed Web of Science ®Google Scholar
• Persson U., Inganas M., Smith C. I., Hammarstrom I., Johansson S. G. Recombinant protein A of non-Staphylococcal origin is not mitogenic for human pheripheral lymphocytes. Mitogenicity of natural protein A is caused by a contaminant. Scand. J. Immunol. 1989; 29: 151
   PubMed Web of Science ®Google Scholar
• Kradin R. L., Boyle L. A., Preffer F. I., Callahan R. J., Barlaikovach M., Strauss H. W., Dubinett S., Kurnick J. T. Tumor-derived interleukin 2 dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol. Immunother. 1987; 24: 76
   PubMed Web of Science ®Google Scholar
• Kradin R., Dubinett S., Mullin J., Boyle L., Strauss H. W., Bourgoin P. M., Preffer F. I., Kurnick J. Treatment of patients with advanced cancer using tumor-infiltrating lymphocytes and interleukin 2. Transplant. Proc. 1988; 20: 336
   PubMed Web of Science ®Google Scholar
• Kradin R. L., Lazarus D. S., Dubinett S. M., Gifford J., Groue B., Kurnick J. T., Preffer F. I., Pinto C. E., Davidson E., Callavan R. J., Strauss H. W. Tumor-infiltrating lymphocytes and interleukin 2 in treatment of advance cancer. Lancet 1989; I: 577
   Google Scholar
• Topallian S. L., Soloman D., Arus F. P., Chang A. E., Freerksen D. L., Linehan W. M., Lotze M. T., Robertson CN., Shipp C. A., Simon P., Simpson C. G., Rosenberg S. A. Immunotherapy of pateints with advance cancer using tumor-infiltrating lymphocytes and recombinant interleukin: a pilot study. J. Clin. Oncol. 1988; 6: 839
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Packard B. S., Aebersold M. P., Soloman D., Topallian S. L., Toy S. T., Slion P., Lotze M. T., Yang J. C., Seipp C. A., Simpson C., Carter C., Bock S., Schwartzentruber D., Wei J. P., White D. E. Use of tumor infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma. New Engl. J. Med. 1988; 319: 1676
   PubMed Web of Science ®Google Scholar
• Moertel C. G. On lymphokines, cytokines and breakthroughs. J. AMA 1986; 256: 1341
   Web of Science ®Google Scholar